Stem cells reverse stroke damage and restore movement in mice

A team at the University of Zurich has shown that transplanted human stem cells can regenerate brain tissue destroyed by stroke and restore lost motor function in mice, reversing damage that is normally permanent. The neural progenitor cells, grown from induced pluripotent stem cells, survived for five weeks inside the injured brain and matured into working neurons that linked up with the animals’ own circuitry. Christian Tackenberg, who leads the neurodegeneration group behind the work, said the results argue for pursuing regenerative approaches to brain injury rather than treating the damage as fixed. Mice that received the cells a week after their stroke moved and walked measurably better than untreated animals.

Human neural stem cells took root and matured

The transplanted cells started as human induced pluripotent stem cells, adult tissue reprogrammed to an earlier developmental state and then steered into becoming neural progenitors before implantation, manufactured without animal-derived reagents so the process could more plausibly scale toward clinical-grade production. Roughly 78 percent of the graft differentiated into mature neurons over the five-week study window, while the remainder split between lingering progenitor cells and support cells called astrocytes. That maturation rate is unusually high for a xenograft, cells from one species surviving inside another, and it is a large part of why the Zurich group is treating the result as more than an incremental step.

Bioluminescence imaging used to track the graft showed a stable signal through day 35, evidence the transplanted cells were not just surviving but settling into the tissue. “[The team] found that the stem cells survived for the full analysis period of five weeks and that most of them transformed into neurons, which actually even communicated with the already existing brain cells,” Tackenberg said in a statement carried by EurekAlert. About 44 percent of the new neurons took on a GABAergic identity and 42 percent became glutamatergic, the two main signaling types in the mammalian cortex, according to findings summarized by ScienceDaily.

Delayed transplantation outperformed immediate treatment

Timing mattered as much as the cells themselves. Grafts placed seven days after the stroke, once the brain’s initial inflammatory surge had begun to subside, survived and integrated far better than cells implanted immediately, when swelling and immune activity in the injury site were still peaking. The delayed group also showed the clearer functional gains.

On the rotarod test, a standard rodent measure of balance and motor coordination, mice given the delayed transplant outperformed untreated stroke mice by a statistically significant margin, and on a ladder-rung crossing task they made fewer missteps by day 35, according to the peer-reviewed paper in Nature Communications. The team scored movement using deep-learning gait analysis rather than manual observation, which the researchers say picked up recovery differences a human observer would likely miss. Rebecca Weber, a postdoctoral researcher in Tackenberg’s group, is listed as the paper’s lead author, with Ruslan Rust of the University of Southern California’s Zilkha Neurogenetic Institute and colleagues in Zurich and Los Angeles coauthoring the study, titled “Neural xenografts contribute to long-term recovery in stroke via molecular graft-host crosstalk.”

The one-week delay is a practical detail as much as a biological one. It gives clinicians, in a hypothetical future human version of the therapy, a diagnostic window to confirm a stroke, stabilize a patient and prepare the graft rather than needing a cell product ready to implant within hours of an event that is itself unpredictable in timing.

Repair extended beyond new neurons

The graft’s benefit was not limited to replacing dead cells. “[The] findings show that neural stem cells not only form new neurons, but also induce other regeneration processes,” Tackenberg said. Transplanted cells triggered new blood vessel growth in the damaged tissue, helped restore the blood-brain barrier’s integrity and reduced inflammation around the injury site.

The graft also appeared to boost the brain’s own repair machinery, increasing activity in the subventricular zone, a region along the brain’s ventricles that continues producing new neural cells throughout life. Researchers describe that combination, a foreign graft nudging the host’s native regeneration alongside its own, as graft-host crosstalk, and it is the mechanism they argue explains why the treated mice recovered function rather than merely gaining extra tissue.

Japan’s Parkinson’s trials point toward the clinic

Stroke remains a leading cause of long-term disability, and no approved therapy currently regrows the tissue it destroys. Tackenberg pointed to Japan as evidence the underlying approach can reach patients: Kyoto University’s Center for iPS Cell Research and Application has already transplanted allogeneic iPS cell-derived dopamine progenitors into people with Parkinson’s disease, reporting the therapy was safe and showed signs of efficacy in a 2025 trial update. “[Researchers] need to minimize risks and simplify a potential application in humans,” Tackenberg said.

Before a stroke version of the therapy could move toward people, the Zurich team says it wants to build a safety switch into the transplanted cells to prevent uncontrolled growth, a standard concern with any therapy built on pluripotent stem cells, which can form tumors if a small number of undifferentiated cells slip through. The group also wants to test whether the graft can be delivered through blood vessels, an endovascular route similar to a stroke thrombectomy, rather than through direct injection into the brain, which would require a more invasive procedure than most stroke patients currently undergo.

Tackenberg’s lab at the university’s Institute for Regenerative Medicine is continuing that work in mouse models, leaving open how many more years of preclinical testing separate the current results from a treatment doctors could actually offer stroke patients.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview